Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Multiple Myeloma

Maria-Victoria Mateos, MD, PhD, consultant physician, hematology department, Hospital Universitario de Salamanca, discusses ixazomib-lenalidomide-dexamethasone in multiple myeloma.

The trial demonstrated that the oral regiman ixazomib-lenalidomide-dexamethasone (IRd) improved progression-free survival (PFS) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

In the past, lenalidomide-dexamethasone was the standard of care, but now there are numerous options for three-drug combinations for patients that have relapsed after one to three prior lines of therapy, says Mateos.

There may be challenges selecting the right three-drug combination, as results are similar between them. The main advantage of IRd is that it is an all oral combination, requiring less hospital visits, says Mateos.